Non-reflow after acute myocardial infarction and reperfusion can lead to complete myocardial necrosis, expansion of myocardial infarction area, damage of cardiac function, left ventricular remodeling and heart failure, which seriously affect the short-term and long-term prognosis of patients, and become a major international problem and research hotspot in the cardiovascular field. Tongxinluo capsule, the representative prescription of collateral disease theory, has increasingly shown its advantages in the treatment of myocardial no-reflow. This article reviews the progress of basic and clinical research on the application of Tongxinluo capsule in the prevention and treatment of this disease in the past 10 years.

Myocardial Infarction,acute;                    No-reflow;                    Collateral Disease Theory;                    Tongxinluo capsule;